|1.||Fujiwara, Hiromi: 3 articles (12/2005 - 07/2002)|
|2.||Imanishi, Takeshi: 3 articles (12/2005 - 07/2002)|
|3.||Ono, Shiro: 2 articles (12/2009 - 02/2003)|
|4.||Yang, Yi-Fu: 2 articles (12/2009 - 02/2003)|
|5.||Matsushima, Kouji: 2 articles (08/2005 - 07/2002)|
|6.||Gao, Ping: 2 articles (02/2003 - 07/2002)|
|7.||Hamaoka, Toshiyuki: 2 articles (02/2003 - 07/2002)|
|8.||Obika, Satoshi: 2 articles (02/2003 - 07/2002)|
|9.||Barroso, Helena: 1 article (01/2012)|
|10.||Borrego, Pedro: 1 article (01/2012)|
12/01/2005 - "TAK-779 treatment may be especially beneficial for young HIV patients as they face lifelong treatment, and this drug impairs atherogenesis."
12/01/2005 - "HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice."
12/01/2005 - "TAK-779 treatment of low-density lipoprotein receptor-deficient mice did not elevate the levels of atherogenic lipoproteins, whereas it dramatically reduced atherosclerosis in the aortic root and in the carotid arteries. "
12/01/2005 - "We investigated whether the HIV entry inhibitor TAK-779 affects lipoprotein levels and atherogenesis in low-density lipoprotein receptor-deficient mice. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
07/05/2005 - "In this study, we show that M-tropic R5 viruses isolated from individuals with acquired immunodeficiency syndrome (late R5 viruses) require lower levels of CD4/CCR5 expression for entry, have decreased sensitivity to inhibition by the entry inhibitors TAK-779 and T-20, and have increased sensitivity to neutralization by the Env MAb IgG1b12 compared with non-M-tropic R5 viruses isolated from asymptomatic, immunocompetent individuals (early R5 viruses). "
01/01/2012 - "The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. "
|3.||Asthma (Bronchial Asthma)
04/01/2008 - "The aim of the present study was to investigate the role of CCR5 and CXCR3 in allergen-induced acute asthma and to determine whether a novel small-molecule compound, TAK-779, targeting CCR5 and CXCR3 can attenuate allergic airway responses. "
04/01/2008 - "These data demonstrate that blockade of CC chemokine receptor 5 and CXC chemokine receptor 3 using TAK-779, a synthetic nonpeptide compound, can prevent the development of asthma features in a mouse model. "
02/01/2003 - "Our preceding study demonstrated that a nonpeptide synthetic CCR5 antagonist, TAK-779 (N, N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6, 7-dihydro-5H-benzocyclohepten-8-yl]carbon-yl]amino]benzyl]-tetrahydro-2H-pyran4-aminium chloride, inhibits the development of experimentally induced arthritis by modulating the migration of CCR5(+)/CXCR3(+) T cells to joints. "
01/01/2011 - "TAK-779 treatment during acute HSV-1 infection reduced the number of infiltrating CD8+ T cells but did not alter the number of viral genome copies. "
01/01/2011 - "HSV-1-infected mice were treated with TAK-779 to block CCR5- and CXCR3-mediated CD8+ T cell migration during both acute and latent infections. "
02/05/2007 - "R5-AIDS env pseudotypes were more resistant to TAK-779 and showed more rapid infection kinetics but similar resistance to a CD4 blocking mAb. We conclude that the enhanced thymic replication and CPE shown by the R5-AIDS clone is due to enhanced efficiency of Env-mediated entry via CCR5."
04/01/2005 - "After warming to 37 degrees C, the completion of entry was monitored over time by the resistance of infections to the competitive CCR5 inhibitor TAK-779. "
11/01/2001 - "Both the CCR5-specific monoclonal antibody 2D7 and TAK-779, a nonpeptide inhibitor of CCR5-mediated viral entry, blocked HIV-1 strain ADA infection by >80%. "
|1.||LDL Receptors (LDL Receptor)
|10.||CCR5 Receptors (CCR5 Receptor)